Exatecan Antibody Drug Conjugates Based on a Hydrophilic Polysarcosine Drug-Linker Platform
We herein report the development and evaluation of a novel HER2-targeting antibody-drug conjugate (ADC) based on the topoisomerase I inhibitor payload exatecan, using our hydrophilic monodisperse polysarcosine (PSAR) drug-linker platform (PSARlink). In vitro and in vivo experiments were conducted in...
Saved in:
Main Authors: | Louise Conilh (Author), Guy Fournet (Author), Eric Fourmaux (Author), Angélique Murcia (Author), Eva-Laure Matera (Author), Benoît Joseph (Author), Charles Dumontet (Author), Warren Viricel (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance
by: Nick Evans, et al.
Published: (2022) -
Antibody-drug conjugates: Recent advances in linker chemistry
by: Zheng Su, et al.
Published: (2021) -
Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate
by: Rotimi Sheyi, et al.
Published: (2022) -
Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy
by: Audrey Nathania Johan, et al.
Published: (2022) -
Polysarcosine-Functionalized mRNA Lipid Nanoparticles Tailored for Immunotherapy
by: Christoph Wilhelmy, et al.
Published: (2023)